Roen Surgical Signs Indonesian Distribution Rights Contract for AI-Based Kidney Stone Surgery Robot

PT Hosp Medic Signs Exclusive Contract with Indonesia
First Export in Second Half... Distribution Expands to Thailand, Taiwan, and More

Surgical robot company Loen Surgical announced on the 7th that it has signed an exclusive distribution rights contract for the kidney stone export robot 'Jamenix' in Indonesia with PT Hospi Medik Indonesia, a medical device specialist company in Indonesia.

The world's first AI-based fully robotic kidney stone surgery robot, Jamenics, developed by Roen Surgical. Photo by Roen Surgical

This contract includes the exclusive right to distribute Jamenix throughout Indonesia, and the contract period is three years. PT Hospi Medik is a sister company of PT Surgika Alkesindo, the largest medical device distribution company in Indonesia, specializing in the distribution of various medical equipment such as surgical instruments, medical imaging devices, radiation, and medical devices.

Loen Surgical completed the regulatory approval registration of Jamenix with the Indonesian Ministry of Health (MOH) in the first half of this year and will begin full-scale exports in the second half. In particular, through this contract, national hospitals plan to distribute Jamenix via PT Hospi Medik, while private hospitals will distribute it through PT Surgika Alkesindo.

Indonesia has a kidney stone prevalence rate of 0.6%, which is higher than the Southeast Asian average. Due to its geographical characteristics of many islands with high salt and lime content in drinking water, related diseases are frequent, and the introduction of the AI-based kidney stone removal robot Jamenix is expected to bring significant changes.

Jamenix is the world's first AI-based fully robotic kidney stone surgery robot that removes stones by passing through the urethra and ureter without incision using a 2.8 mm flexible endoscope. By applying AI technology, it monitors the movement of stones caused by the patient's breathing and improves surgical precision, enhancing patient safety and medical staff convenience.

Loen Surgical plans to expand distribution in Asian markets such as Thailand and Taiwan, using the Indonesian contract as a foothold. It began promoting Jamenix earlier this year through urology societies in Thailand and Taiwan and intends to accelerate the expansion of its global market share.

Kwon Dong-su, CEO of Loen Surgical, said, "Since last year, we have participated in various international conferences to confirm the needs of urology specialists for kidney stone surgery robots and interest in Jamenix," adding, "We will expand distribution starting with the Asian market to help more patients with intractable kidney stones."